Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
PSL 11th Edition: Multan Sultans beat Hyderabad Kingsmen by six wickets
- 30 minutes ago
Sale dominates A's despite being 'sick as a dog'
- 5 hours ago
Pats' Vrabel doesn't dismiss Brown trade chatter
- 5 hours ago
NFLPA: Player safety requires trained, pro refs
- 5 hours ago
World anxious to open Hormuz Strait while Trump and Iran trade threats
- 5 hours ago
QB Mendoza puts on show at Indiana pro day
- 5 hours ago
6.3-magnitude earthquake rocks Islamabad, Punjab, KP
- 43 minutes ago
Fuel crisis: Sindh announces Rs2,000 subsidy for bikers
- 6 hours ago
Rooney: Rodgers to make decision before draft
- 5 hours ago
Mets' Lindor on gaffes: 'Should have been better'
- 5 hours ago
Punjab, Islamabad announce free public transport travel for one month amid 'abrupt' fuel price hike
- 6 hours ago
World food price rise set to continue if Iran war lasts, FAO says
- 6 hours ago
